Popular Blog Posts
Viagra User Speaks Out|
Saved our love life
Does Sex Hurt The First Time?
Pain conditions during...
How To Bust Weak Erections
With 3 Strategies..
Learn Premature Ejaculation Control
The facts PE...
Click for more Blog posts...
Ranbaxy Launches Flotral Drug Treatment For Prostate Gland Enlargement BPHCORPORATE BUREAU
Ranbaxy Laboratories: Newsroom > Press Releases > New Delhi, Nov 22
Ranbaxy Laboratories Ltd has announced the launch of its benign prostatic hyperplasia (BPH) formulation, Flotral 10 mg or Alternative Tamsulosin formulation. It is a new uro-selective alpha1-blocker, prescription medicine that provides effective medical relief from signs and symptoms of BPH, a urological disorder.
Flotral (alfuzosin), once a day medication, has been developed using the Novel Drug Delivery System (NDDS) technology platform, resulting in better patient compliance, the company said in a statement.
[Prostate Cancer survivor]
[Obesity Health Online]
[Weight loss fitness exercise training]
It is a new, convenient and safe formulation. Extensive clinical studies demonstrate that alfuzosin is highly selective resulting in
lower incidence of side effects such as postural hypotension and syncope.
If left untreated, BPH can lead to serious health problems, including urinary tract infections, bladder and kidney damage, bladder stones and inability to hold urine, it added.
The launch of Flotral further expands Ranbaxy's key strategic product portfolio and establishes the company's commitment to build its urology franchise through its competitive edge technology of NDDS, Sanjeev I Dani, regional director-India, Ranbaxy, stated.
Ranbaxy's foray into Novel Medical Drug Delivery Systems has led to proprietary "platform technologies" resulting in a number of products under development. The Company is selling its products in over 100 countries andhas an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 34 countries and manufacturing operations in 7 countries.